What is HC Wainwright’s Estimate for AUTL Q1 Earnings?

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Autolus Therapeutics in a research report issued to clients and investors on Tuesday, February 17th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings of ($0.28) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Autolus Therapeutics’ Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.11) EPS and FY2029 earnings at ($0.42) EPS.

Other equities research analysts have also issued reports about the stock. Needham & Company LLC reduced their price objective on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, January 12th. Zacks Research cut shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, January 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Autolus Therapeutics in a research report on Wednesday, January 21st. Finally, Wall Street Zen downgraded Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 15th. Five research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $8.50.

Autolus Therapeutics Trading Up 5.1%

Shares of AUTL opened at $1.64 on Thursday. The stock’s 50-day moving average price is $1.58 and its two-hundred day moving average price is $1.57. Autolus Therapeutics has a 12 month low of $1.11 and a 12 month high of $2.70. The company has a market capitalization of $436.47 million, a PE ratio of -1.98 and a beta of 1.98.

Hedge Funds Weigh In On Autolus Therapeutics

Several hedge funds have recently modified their holdings of AUTL. Marex Group plc purchased a new position in shares of Autolus Therapeutics in the 2nd quarter worth about $28,000. Independent Advisor Alliance bought a new stake in Autolus Therapeutics in the fourth quarter worth about $28,000. SmartHarvest Portfolios LLC purchased a new position in Autolus Therapeutics in the fourth quarter valued at about $43,000. R Squared Ltd purchased a new position in Autolus Therapeutics in the second quarter valued at about $50,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of Autolus Therapeutics during the 3rd quarter valued at approximately $46,000. Institutional investors own 72.83% of the company’s stock.

Key Autolus Therapeutics News

Here are the key news stories impacting Autolus Therapeutics this week:

• Positive Sentiment: HC Wainwright initiated/expanded coverage on AUTL with Buy / Strong‑Buy ratings and a $9.00 target (roughly a large percentage upside vs current levels), giving the stock fresh bullish analyst support that likely drove buying interest. Read More. | Read More. | Read More.
• Positive Sentiment: HC Wainwright released a series of forward EPS forecasts and quarterly estimates (Q1–Q4 and multi‑year views) paired with the bullish ratings — this provides a detailed analyst roadmap investors can trade around. Read More.
• Neutral Sentiment: Short-interest data in recent filings appears malformed (reported as 0 shares and NaN change), so there’s no clear short-selling signal to explain recent flows; treat short-interest reporting as unreliable until corrected. Read More.
• Negative Sentiment: Consensus and HC Wainwright EPS estimates remain negative across near‑ and medium‑term horizons (company expected to continue reporting losses per their model), which means the stock is highly dependent on clinical/operational milestones and sentiment rather than current earnings. Read More.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.